Camille Mojica Rey

Camille Mojica Rey

Camille Mojica Rey, Ph.D., is a freelance writer with more than 17 years of experience in journalism and science communication. Camille specializes in the translation of medical science for lay audiences and began writing about the business of biotech in 2016. The subject hits close to home: her husband, a Silicon Valley biotech veteran, now works as a scientist at an Austin-based company. Camille earned a B.A. in Biology from the University of Texas at Austin, a Ph.D. from the University of California, Berkeley, and a certificate in Science Communication from UC Santa Cruz. She has worked for major academic medical centers, including UC San Francisco and Stanford University. She has also worked for the San Jose Mercury News and Latina magazine. Her freelance work has appeared on CNN.com, in Science magazine, and on NPR's Latino USA. Starting in 2017, Camille began teaching writing workshops and facilitating writing retreats for academic and industry scientists.

ARTICLES BY CAMILLE MOJICA REY

  • Pharmas That Build Unique Corporate Cultures
    Pharmas That Build Unique Corporate Cultures

    Creating unique cultures that motivate your inherently diverse teams for the long haul to FDA approval is the secret to recruitment and retention in pharma where competition for highly skilled workers is fierce. It is also the key to achieving high performance and employee satisfaction.

  • The Art Of Leadership
    The Art Of Leadership

    Former Pfizer exec and current partner at VC firm Polaris Partners Amy Schulman talks about what it takes to lead a pharma startup.

  • One Small Startup’s Quest For Funding Gets Creative
    One Small Startup’s Quest For Funding Gets Creative

    As CEO of Ensysce Biosciences, a semi-virtual company with three employees, Lynn Kirkpatrick, Ph.D., knows all about the funding struggles of a small company.

  • Will Value-Based Drug Pricing Work?
    Will Value-Based Drug Pricing Work?

    Drug companies have begun experimenting with value-based models, largely in response to public outrage over the cost of prescription drugs and the U.S. government’s efforts to rein in those costs.

  • Value-Based Healthcare: Pharma’s Role In The Transition
    Value-Based Healthcare: Pharma’s Role In The Transition

    This is the first in a two-part series on value-based healthcare. In Part II, Life Science Leader will look at value-based models used to determine the price of drugs.

  • Diversification Relieves Funding Pressure For Small Pharma
    Diversification Relieves Funding Pressure For Small Pharma

    Chronic pressure is a way of life for those starting pharmaceutical companies. It’s a life filled with rounds of funding, investor demands, performance deadlines, and possible compound failures. But what if the technology owned by a startup drug discovery company was suddenly in demand by some of the world’s largest food and beverage corporations? What if that opportunity gives you the flexibility and time to conduct your research on your own timetable?

  • Preparing For A Blockchain-Enabled World
    Preparing For A Blockchain-Enabled World

    Ask life sciences industry leaders and experts about blockchain and you will hear it called everything from “a game changer” to “a major disrupter.” According to the hype, the technology behind cryptocurrencies, like bitcoin, is going to completely transform day-to-day operations for life sciences companies.

  • New Hampshire: A Biotech Microhub
    New Hampshire: A Biotech Microhub

    As the biotech sector in the U.S. continues to grow, it is doing so not just in hubs, but in smaller places like New Hampshire — where some of the state’s biopharma entrepreneurs say: “Smaller is better.”

  • CEOs 40 & Under: The Future of Pharma Innovation
    CEOs 40 & Under: The Future of Pharma Innovation

    To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.

  • Awakening The Biotech Entrepreneurial Spirit
    Awakening The Biotech Entrepreneurial Spirit

    Roger Newton still remembers the day in November of 1997 when he tripped over a pile of books in a Borders Bookstore in Ann Arbor, MI. He looked down on a back cover of one of the books to see the words: “Don’t let your company kill you.” He turned the book over and saw the title of Robert E. Quinn’s book, Deep Change: Discovering the Leader Within. His life and career would never be the same.

  • Amorsa’s Self-Funded Path To Big Pharma Partnerships
    Amorsa’s Self-Funded Path To Big Pharma Partnerships

    Amorsa Therapeutics has accomplished something rare — if not unheard of. The company, founded in 2013, was self-funded for three years before entering into a strategic partnership with Janssen Pharmaceuticals in January 2017. This journey was made possible by industry experience, scientific expertise, and rock-solid confidence in their choice of therapeutic target.

  • Can DalCor Pharma Succeed Where Others Have Failed?
    Can DalCor Pharma Succeed Where Others Have Failed?

    After the worldwide success of statins, no one expected the epic failure of a class of drugs designed by the biggest names in Big Pharma to double the reduction in cardiac risk seen with statins alone. Statins lowered LDL, the bad cholesterol. The new drugs, called cholesteryl ester transfer protein (CETP) inhibitors, would raise HDL, the good cholesterol. Taken together, the drugs would reduce risk of cardiovascular events by up to 80 percent — or at least that was the idea.

  • Is Marking Individual Doses The Future Of Anticounterfeiting?
    Is Marking Individual Doses The Future Of Anticounterfeiting?

    The last in our five-part series examining the current state of the counterfeit medicines problem. Previous stories looked at efforts to quantify the crime, examined the issue from the perspective of the industry giant Pfizer, described how an international coalition is fighting the crime, and highlighted the latest programs aimed at teaching the public how to safely shop for medicines online.

  • Educating Consumers About The Risks Of Counterfeit Medicines
    Educating Consumers About The Risks Of Counterfeit Medicines

    This is the final article in a four-part Life Science Leader series examining the current state of the counterfeit medicines problem. Previous stories looked at efforts to quantify the crime, examined the issue from the perspective of industry giant Pfizer, and described what is being done by an international coalition to fight the crime.

  • State Funding Fuels Michigan’s Life Sciences Industry
    State Funding Fuels Michigan’s Life Sciences Industry

    Following the Great Recession of 2007-09, leaders in Michigan came up with a plan for diversifying its industries. The state’s dependence on the automobile industry, the country’s largest, had threatened to cripple its entire economy until the federal government intervened. The state — and the companies — might not be so lucky next time. So, the plan for a more diversified Michigan of the future includes looking to one of its core industries of the past: the life sciences.

  • The Worldwide War On Counterfeit Medicines
    The Worldwide War On Counterfeit Medicines

    It’s a sobering trend for the pharmaceutical industry. The counterfeit medicines market is growing at twice the rate of the market for legitimate prescription drugs. So what can be done?

  • Why Xellia Revived A Shuttered Pharma Facility
    Why Xellia Revived A Shuttered Pharma Facility

    As he walked through the former home of Ben Venue Laboratories, Niels Lynge Agerbæk didn’t see the previous failures the facility had endured.

  • Pfizer’s Response To Counterfeit Drugs
    Pfizer’s Response To Counterfeit Drugs

    This is the second article in a five-part Life Science Leader series examining the current state of the counterfeit medicines problem. A previous story looked at efforts to quantify the crime. Upcoming stories will look at what is being done by one international coalition to fight the crime, describe efforts to educate patients, and profile a company working to put unique identifiers on individual pills.

  • Building A Biotech Hub – Austin Style
    Building A Biotech Hub – Austin Style

    There is a serious push to make Texas the “Third Coast” of biotech and Austin, in particular, a new hub for the industry.

  • Getting An Accurate Count Of Counterfeit Drugs
    Getting An Accurate Count Of Counterfeit Drugs

    The first of a four-part, in-depth series on the ongoing problem of counterfeit medicines. In this article, we talk about how the Counterfeit Incidence System (CIS) is better tracking the number of law enforcement cases involving pharmaceutical crimes.

More From Articles by Camille Mojica Rey